Navigating the New Complexity of Multiple Myeloma Treatment

By Gina ShawJordan Snyder, PharmDFour years ago, VRd (bortezomib, lenalidomide, dexamethasone) was the standard induction regimen for newly diagnosed multiple myeloma. Today, oncology pharmacists are managing quadruplet regimens up front, fielding questions about whether transplant is still necessary, counseling patients through chimeric antigen receptor T-cell (CAR-T) therapy in second-line relapse, and sequencing bispecific T-cell engagers (BiTEs) across a field of four commercially available